Exclusivity Patents and exclusivity Drug Information Prescribing and other information DMFs Type 2 master files Databases Free access to database search 21 CFR FDA regulations for this API Federal Register FR search results for this API Drug Recalls For Rx's using this API

FDA Approval Activities for this Drug… CellCept (mycophenolate mofetil hydrochloride) Intravenous, for injection/new injection, Roche Global Development NDA 50-758 8/12/98 11/12/98 CellCept Indication: Prophylaxis of organ rejection in patients receiving allogeneicrenal transplants and in patients receiving allogeneic cardiac transplants. CellCept (mycophenolate mofetil hydrochloride) Intravenous / Suspension / Capsules / Tablets, Hoffman La-Roche NDA 50-722/SE5-007, 50-723/SE5-004, 50-759/SE5-005 12/22/00 12/26/00 12/26/00 11/1/01 CellCept (mycophenolate mofetil hydrochloride) Intravenous / Suspension / Capsules / Tablets, Hoffman La-Roche, NDA 50-722/SE1-008, 50-723/SE1-006, 50-758/SE1-005, 50-759/SE1-008 2/28/03 3/10/03 3/11/03 | CellCept (mycophenolate mofetil hydrochloride) Intravenous / Suspension / Capsules / Tablets, Hoffman La-Roche NDA 50-722/SE1-005, 50-723/SE1-005, 50-758/SE1-004, 50-759/SE1-006 Myfortic (Mycophenolic Acid) Delayed-Release Tablets, Novartis Pharmaceuticals | CellCept Intravenous (mycophenolate mofetil hydrochloride) injection, Hoffmann-La Roche, Labeling Revision | CellCept (mycophenolate mofetil) Capsules, Hoffmann-La Roche, Labeling Revision | CellCept (mycophenolate mofetil) Tablets, Hoffmann-La Roche, Labeling Revision | CellCept (mycophenolate mofetil hydrochloride) Injection, Hoffmann-La Roche, Labeling Revision | CellCept (mycophenolate mofetil hydrochloride) Oral Suspension, Hoffmann-La Roche, Labeling Revision Check the most up-to-date list of FDA Approvals.   A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U-Z Health Topics | News Feed for each API | DMF Index | Pharma Job Search | FindingHealthOnline © 2008 Betterchem.com